Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma

Clinical article

Restricted access

Object

Temozolomide (TMZ) may enhance antitumor immunity in patients with glioblastoma multiforme (GBM). In this paper the authors report on a prospective Phase I/IIa clinical trial of fractionated radiotherapy (FRT) concomitant with TMZ therapy, followed by treatment with autologous formalin-fixed tumor vaccine (AFTV) and TMZ maintenance in patients with newly diagnosed GBM.

Methods

Twenty-four patients (age 16–75 years, Karnofsky Performance Scale score ≥ 60% before initiation of FRT) with newly diagnosed GBM received a total dose of 60 Gy of FRT with daily concurrent TMZ. After a 4-week interval, the patients received 3 AFTV injections and the first course of TMZ maintenance chemotherapy for 5 days, followed by multiple courses of TMZ for 5 days in each 28-day cycle.

Results

This treatment regimen was well tolerated by all patients. The percentage of patients with progression-free survival (PFS) ≥ 24 months was 33%. The median PFS, median overall survival (OS), and the actuarial 2- and 3-year survival rates of the 24 patients were 8.2 months, 22.2 months, 47%, and 38%, respectively. The median PFS in patients with a delayed-type hypersensitivity (DTH) response after the third AFTV injection (DTH-2) of 10 mm or larger surpassed the median length of follow-up for progression-free patients (29.5 months), which was significantly greater than the median PFS in patients with a smaller DTH-2 response.

Conclusions

The treatment regimen was well tolerated and resulted in favorable PFS and OS for newly diagnosed GBM patients. Clinical trial registration no.: UMIN000001426 (UMIN clinical trials registry, Japan).

Abbreviations used in this paper:AFTV = autologous formalin-fixed tumor vaccine; CREIL Center = Critical Path Research and Education Integrated Leading; CTCAE = Common Terminology Criteria for Adverse Events; DTH = delayed-type hypersensitivity; FRT = fractionated radiotherapy; GBM = glioblastoma multiforme; IDH1 = isocitrate dehydrogenase-1; JBTRC = Japan Brain Tumor Reference Center; KPS = Karnofsky Performance Scale; MGMT = O6-methylguanine-DNA methyltransferase; MHC = major histocompatibility complex; MRC = Medical Research Council; OS = overall survival; PFS = progression-free survival; RPA = recursive partitioning analysis; TMZ = temozolomide.
Article Information

Contributor Notes

Address correspondence to: Eiichi Ishikawa, M.D., Ph.D., Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan. email: e-ishikawa@md.tsukuba.ac.jp.Please include this information when citing this paper: published online July 4, 2014; DOI: 10.3171/2014.5.JNS132392.

© Copyright 1944-2019 American Association of Neurological Surgeons

Headings
References
  • 1

    Al-Batran SERafiyan MRAtmaca ANeumann AKarbach JBender A: Intratumoral T-cell infiltrates and MHC class I expression in patients with stage IV melanoma. Cancer Res 65:393739412005

    • Search Google Scholar
    • Export Citation
  • 2

    Clarke JLIwamoto FMSul JPanageas KLassman ABDeAngelis LM: Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 27:386138672009

    • Search Google Scholar
    • Export Citation
  • 3

    Committee of Brain Tumor Registry of Japan: Report of Brain Tumor Registry of Japan (1969–1996). Neurol Med Chir (Tokyo) 43:Supplivii11112003

    • Search Google Scholar
    • Export Citation
  • 4

    Curran WJ JrScott CBHorton JNelson JSWeinstein ASFischbach AJ: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:7047101993

    • Search Google Scholar
    • Export Citation
  • 5

    Ishikawa ETsuboi KTakano SUchimura ENose TOhno T: Intratumoral injection of IL-2-activated NK cells enhances the antitumor effect of intradermally injected paraformaldehy-defixed tumor vaccine in a rat intracranial brain tumor model. Cancer Sci 95:981032004

    • Search Google Scholar
    • Export Citation
  • 6

    Ishikawa ETsuboi KYamamoto TMuroi ATakano SEnomoto T: Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients. Cancer Sci 98:122612332007

    • Search Google Scholar
    • Export Citation
  • 7

    Ishikawa EYamamoto TSakamoto NNakai KAkutsu HTsuboi K: Low peripheral lymphocyte count before focal radiotherapy plus concomitant temozolomide predicts severe lymphopenia during malignant glioma treatment. Neurol Med Chir (Tokyo) 50:6386442010

    • Search Google Scholar
    • Export Citation
  • 8

    Iversen TZBrimnes MKNikolajsen KAndersen RSHadrup SRAndersen MH: Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. OncoImmunology 2:e232882013

    • Search Google Scholar
    • Export Citation
  • 9

    Kim IHPark CKHeo DSKim CYRhee CHNam DH: Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. J Neurooncol 103:5956022011

    • Search Google Scholar
    • Export Citation
  • 10

    Kim TGKim CHPark JSPark SDKim CKChung DS: Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol 17:1431532010

    • Search Google Scholar
    • Export Citation
  • 11

    Kocher MFrommolt PBorberg SKRühl USteingräber MNiewald M: Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 184:5725792008

    • Search Google Scholar
    • Export Citation
  • 12

    Kuang MPeng BGLu MDLiang LJHuang JFHe Q: Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin Cancer Res 10:157415792004

    • Search Google Scholar
    • Export Citation
  • 13

    Liu GBlack KLYu JS: Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination. Expert Rev Vaccines 5:2332472006

    • Search Google Scholar
    • Export Citation
  • 14

    Mitchell DACui XSchmittling RJSanchez-Perez LSnyder DJCongdon KL: Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood 118:300330122011

    • Search Google Scholar
    • Export Citation
  • 15

    Muragaki YMaruyama TIseki HTanaka MShinohara CTakakura K: Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article. J Neurosurg 115:2482552011. (Erratum in J Neurosurg 118: 709 2013)

    • Search Google Scholar
    • Export Citation
  • 16

    Ohno T: Autologous formalin-fixed tumor vaccine. Curr Pharm Des 11:118111882005

  • 17

    Sakamoto NIshikawa EYamamoto TSatomi KNakai KSato M: Pathological changes after autologous formalin-fixed tumor vaccine therapy combined with temozolomide for glioblastoma. Three case reports. Neurol Med Chir (Tokyo) 51:3193252011

    • Search Google Scholar
    • Export Citation
  • 18

    Sampson JHHeimberger ABArcher GEAldape KDFriedman AHFriedman HS: Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:472247292010

    • Search Google Scholar
    • Export Citation
  • 19

    Sanchez-Perez LAChoi BDArcher GECui XFlores CJohnson LA: Myeloablative temozolomide enhances CD8+ T-cell responses to vaccine and is required for efficacy against brain tumors in mice. PLoS ONE 8:e590822013

    • Search Google Scholar
    • Export Citation
  • 20

    Smith KAAshby LSGonzalez LFBrachman DGThomas TCoons SW: Prospective trial of gross-total resection with Gliadel wafers followed by early postoperative Gamma Knife radiosurgery and conformal fractionated radiotherapy as the initial treatment for patients with radiographically suspected, newly diagnosed glioblastoma multiforme. J Neurosurg 109:Suppl1061172008. (Errata in J Neurosurg 110:1323–1324 2009 and J Neurosurg 111: 639 2009)

    • Search Google Scholar
    • Export Citation
  • 21

    Steiner HHBonsanto MMBeckhove PBrysch MGeletneky KAhmadi R: Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 22:427242812004

    • Search Google Scholar
    • Export Citation
  • 22

    Stummer WMeinel TEwelt CMartus PJakobs OFelsberg J: Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 108:89972012

    • Search Google Scholar
    • Export Citation
  • 23

    Stupp RHegi MEMason WPvan den Bent MJTaphoorn MJJanzer RC: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:4594662009

    • Search Google Scholar
    • Export Citation
  • 24

    Takano SKato YYamamoto TKaneko MKIshikawa ETsujimoto Y: Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 108:3613732012

    • Search Google Scholar
    • Export Citation
  • 25

    Trotti AColevas ADSetser ARusch VJaques DBudach V: CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:1761812003

    • Search Google Scholar
    • Export Citation
TrendMD
Cited By
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 838 754 125
PDF Downloads 229 169 2
EPUB Downloads 0 0 0
PubMed
Google Scholar